THE NEXT WAVE: 2011 Pipeline Report

Armstrong, Walter
February 2011
Pharmaceutical Representative;Feb2011, Vol. 41 Issue 2, p12
The article presents information related to advance and breakthroughs in medical science. It reveals the new classes of protein inhibitors that increases the cure rate of Hepatitis C by 50 percent. It notes the modern approaches in preventing the disease progression of multiple sclerosis. It discusses the new treatment for cancer specifically the previously considered untreatable triple-negative breast cancer.


Related Articles

  • Letter to the Editor. Mert, Ali; Atlintas, Ayse; Ozaras, Resat; Bilir, Muammer; Tabak, Fehmi; Ozturk, Recep; Siva, Aksel; Aktuglu, Yildirim; Senturk, Hakan // Multiple Sclerosis (13524585);Oct2000, Vol. 6 Issue 5, p364 

    Presents a letter to the editor of the periodical 'Multiple Sclerosis,' which appeared in the October 2000 issue concerning the prevalence of serum antibodies to hepatitis C virus (HCV) in patients with multiple sclerosis (MS). Reason for the autoimmunity to myelin proteins in humans; Effect of...

  • Interferon-α.  // Reactions Weekly;1/26/2008, Issue 1186, p25 

    The article describes the case of a woman who developed an acute multiple sclerosis-like demyelinating disease after receiving interferon-α for chronic hepatitis C virus infection. The medical condition of the patient is discussed. Her neurological symptoms worsened after receiving high-dose...

  • Pathology Elsewhere. Ruliang Xu // Laboratory Investigation (00236837);Jun2004, Vol. 84 Issue 6, p665 

    Discusses some issues related to pathology. Identification of unique molecular signatures in gastric cancers through a combination of comparative genomic hybridization and global gene expression profiling analyses; Effects of hepatitis C virus core on hepatic stellate cells; Investigation...

  • HCV protein causes cancer.  // AIDS Patient Care & STDs;Dec98, Vol. 12 Issue 12, p943 

    Discusses findings of Japanese researchers that the hepatitis C virus (HVC) core protein induces hepatocellular carcinoma. Development of hepatic steatosis in laboratory mice as histologic feature of chronic hepatitis C; Characteristics of mice carrying HCV envelope genes.

  • Incomplete response of interferon treatment has an important role for the prevention of hepatocellular carcinoma. Hayashi, Norio // Journal of Gastroenterology;1999, Vol. 34 Issue 5, p655 

    Editorial. Focuses on the incidence of hepatocellular carcinoma (HCC) in Japan. Incidence rate of HCC in cirrhotic patients with antibodies to hepatitis C virus (HCV); Treatment of HCV.

  • Iron, hepatitis C virus, and hepatocellular carcinoma: iron reduction preaches the gospel for chronic hepatitis C. Fujita, Naoki; Takei, Yoshiyuki // Journal of Gastroenterology;Nov2007, Vol. 42 Issue 11, p923 

    The article discusses various reports publishes within the issue, including one on chronic hepatitis C virus and another on iron reduction.

  • Implications of Anemia in Human Immunodeficiency Virus, Cancer, and Hepatitis C Virus. Mildvan, Donna // Clinical Infectious Diseases;11/15/2003 Supplement, Vol. 37, pS293 

    Anemia is a multifactorial problem in patients with human immunodeficiency virus (HIV) infection, cancer, and hepatitis C virus (HCV) infection. New insights regarding anemia symptoms and quality of life (QOL) have prompted reassessment of traditional triggers for anemia treatment to increase...

  • Interferon Therapy after Tumor Ablation Improves Prognosis in Patients with Hepatocellular Carcinoma Associated with Hepatitis C Virus. Shiratori, Yasushi; Shiina, Shuichiro; Teratani, Takuma; Imamura, Masatoshi; Obi, Shun'taro; Sato, Shin'pei; Koike, Yukihiro; Yoshida, Haruhiko; Omata, Masao // Annals of Internal Medicine;2/18/2003, Vol. 138 Issue 4, p299 

    Studies the efficacy of interferon therapy in patients with hepatocellular carcinoma associated with hepatitis C virus. Criteria for interferon response; Factors associated with sustained response; Adverse events and tolerance; Development of foci of hepatocellular carcinoma; Survival rate of...

  • Core promoter mutations 3 years after anti-hepatitis B e seroconversion in patients with chronic hepatitis B or hepatitis B and C infection and cancer remission. Zampino, Rosa; Marrone, Aldo; Karayiannis, Peter; Cirillo, Grazia; Miraglia del Giudice, Emanuele; Rania, Giovanni; Utili, Riccardo; Ruggiero, Giuseppe // American Journal of Gastroenterology;Sep2002, Vol. 97 Issue 9, p2426 

    OBJECTIVES:In this study, we aimed to evaluate the persistence of hepatitis B virus (HBV) DNA and the role of HBV core promoter and precore region mutations in 28 young cancer survivor patients with HBV or HBV and hepatitis C virus (HCV) infections, and persistently normal ALT levels, after...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics